瑞士Octapharma www.octapharma.com
總部位于瑞士 Lachen 的 Octapharma Group 是全球最大的血漿制品制造商之一，過去25年多來一直致力于病患護理和醫(yī)療創(chuàng)新。Octapharma 的核心業(yè)務是從人類血漿和人類細胞系中開發(fā)、生產(chǎn)和銷售高品質(zhì)的人類蛋白質(zhì)療法，其中包括免疫球蛋白靜脈注射 (IGIV)。在美國，Octapharma 的 IGIV 產(chǎn)品 octagam(R)（5%免疫球蛋白[人體]靜脈注射液）被用于治療各種免疫系統(tǒng)疾病，而該公司的 Albumin（人體）則能夠恢復和維持循環(huán)血量。Octapharma 擁有3000多名員工，并在包括美國在內(nèi)的全球80個國家擁有生物制藥經(jīng)驗。Octapharma USA 坐落于新澤西州霍伯肯。Octapharma 經(jīng)營著兩家經(jīng)美國 FDA 許可的一流生產(chǎn)基地，最大程度地提高了生產(chǎn)靈活性，并將產(chǎn)品短缺降至最低。
瑞士Octapharma
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality human proteins.
The company has grown to 3,000 employees in 28 countries since its founding in 1983. Octapharma owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico. Sales turnover in 2008 reached Euro 886 million.
Octapharma continues to grow and invest heavily in the future. Profits, are mainly channelled into R&D and further improvements and expansion of Production.
In the highly demanding market of life-saving plasma products, company success is only possible through reliable product quality and a proven safety record.

Octapharma Mission
Since the foundation of Octapharma in 1983, the company has established a clear and consistent mission: for the safe and optimal use of plasma.
This mission statement has stood the test of time and has driven our activities in the last 26 years.
Over the past six years, in addition to our plasma-based activities, Octapharma has dedicated increasing resources to recombinant product research and development based on the use of human cell lines.
Our recombinant R&D department in Sweden has completed pre-clinical toxicology testing in animals and clinical trials in humans will start in 2009.
This unique approach sets us apart from other companies whose recombinant products are based on animal (murine) cells.

For the safe and optimal use of human proteins
Octapharma respects donated human plasma as a scarce and valuable resource. By using leading edge, validated viral inactivation and purification technologies Octapharma aims to achieve the highest production yields and produce products with the highest possible safety margins.